Covalon Technologies Ltd.
Recent
price
P/E
ratio
div
yld
3.76%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Covalon Technologies Ltd. is a research-driven developer, manufacturer and marketer of patent-protected medical products focused on advanced wound care, infection management, vascular access, perioperative care and customized medical device coatings. The company offers a comprehensive portfolio of solutions including collagen matrix dressings such as ColActive Plus and ColActive Plus Ag for chronic and infected wounds like diabetic foot ulcers, pressure ulcers and surgical wounds; vascular access products including VALGuard line guards, IV Clear dual-antimicrobial clear IV dressings and CovaClear IV soft silicone dressings for sensitive skin; perioperative care items; urology products; and proprietary coating technologies like CovaCoat utilizing photo-polymerization processes. Founded in 2004 and headquartered in Mississauga, Ontario, Canada, Covalon sells its branded products directly and through private label arrangements and license contracts to pediatric and acute care hospitals, long-term care settings and home healthcare providers throughout the United States, Canada, Latin America and the Middle East. In a significant recent development, the company engaged Origin Merchant Partners in May 2025 as its financial and strategic advisor to explore opportunities including joint ventures, mergers, licensing deals, a potential NASDAQ listing, stock repurchases from its approximately $18 million net cash reserves and separations of its Advanced Wound Care and Vascular Access Surgical Consumables divisions to maximize shareholder value; additionally, Covalon announced its first-ever dividend payment in November 2025, marking a milestone in financial strength amid revenue growth to $24.1 million in the first nine months of fiscal 2025.
Company News
Contamination Protection Solution Highlights Covalon's Presence at the Association for Vascular Access 2026 Annual Scientific Meeting
Covalon to Present at the 2026 Annual Smallcap Discoveries Conference After Reporting Revenue Growth of 20% and Gross Margin of 67%
Covalon Technologies Ltd. (COV:CA) Q3 2026 Earnings Call Transcript
Covalon Reports Fiscal 2026 Third Quarter Results
Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2026 Results
Covalon Announces Appointment of New Director and DSU Grants
Covalon Technologies Ltd. (COV:CA) Q2 2026 Earnings Call Transcript
Covalon Reports 2026 Second Quarter Results
Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results
Comparing Solana (NASDAQ:HSDT) and Covalon Technologies (OTCMKTS:CVALF)
Covalon Technologies Reports Significant Milestones Spanning Vascular Access, Infection Prevention, and Wound Care
Covalon to Showcase Clinical Innovation and Infection Prevention Leadership at Infusion Nurses Society 2026 Annual Meeting
Covalon Announces Grant of Deferred Share Units
Covalon Announces Voting Results from Fiscal 2025 Annual General and Special Meeting of Shareholders
Covalon Technologies Ltd. (COV:CA) Shareholder/Analyst Call Transcript
Covalon To Hold Annual Meeting of Shareholders on Wednesday, March 25, 2026
Covalon Technologies Ltd. (COV:CA) Q1 2026 Earnings Call Transcript
Covalon Reports on 2026 First Quarter Results and Recent Achievements and Highlights
Covalon Honoured to Partner with the Association for Vascular Access and Global Expert Dr. Nancy Moureau to Tackle Critical IV Therapy Complications
Covalon Announces Conference Call to Discuss First Quarter Fiscal 2026 Results